PFE Stock Recent News

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.

Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.

Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.

Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. The oncology business shows promising growth, particularly with products like Xtandi and Lobrena, supporting Pfizer's long-term potential. Pfizer's guidance for FY 2024 EPS has been raised, indicating strong earnings potential and undervaluation by the market.

Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years?

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the world's poorest nations at not-for-profit prices, just over two years after it launched.